Loading...
FHTX logo

Foghorn Therapeutics Inc.NasdaqGM:FHTX 주식 보고서

시가총액 US$247.8m
주가
US$4.22
US$11.44
63.1% 저평가 내재 할인율
1Y1.9%
7D11.3%
1D
포트폴리오 가치
​
보기

Foghorn Therapeutics Inc.

NasdaqGM:FHTX 주식 리포트

시가총액: US$247.8m

Foghorn Therapeutics (FHTX) 주식 개요

임상 단계의 바이오 제약 회사인 포그혼 테라퓨틱스는 미국에서 염색질 조절 시스템 내에서 유전적으로 결정된 의존성을 표적으로 하는 의약품을 발견하고 개발하는 회사입니다. 자세히 보기

FHTX 펀더멘털 분석
스노우플레이크 점수
가치 평가3/6
미래 성장2/6
과거 실적0/6
재무 건전성3/6
배당0/6

강점

수익은 연간 34.28% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 5.2% 증가했습니다.

분석가들은 주가가 171.2% 상승할 것이라는 데 동의합니다.

위험 분석

마이너스 주주 지분

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.


FHTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Foghorn Therapeutics Inc. 경쟁사

가격 이력 및 성과

Foghorn Therapeutics 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$4.22
52주 최고가US$6.95
52주 최저가US$3.27
베타2.97
1개월 변동-20.53%
3개월 변동-26.61%
1년 변동1.93%
3년 변동-30.59%
5년 변동-59.46%
IPO 이후 변동-76.71%

최근 뉴스 및 업데이트

분석 기사 • May 11

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report

Shareholders might have noticed that Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) filed its quarterly result this time...

Recent updates

분석 기사 • May 11

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report

Shareholders might have noticed that Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) filed its quarterly result this time...
분석 기사 • Dec 23

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders would be excited to see that the share price has had a great...
분석 기사 • Dec 19

Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Sep 07

We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Jul 10

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares May Have Run Too Fast Too Soon

With a price-to-sales (or "P/S") ratio of 13.1x Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) may be sending very bearish...
분석 기사 • Apr 09

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

The Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) share price has fared very poorly over the last month, falling by a...
Seeking Alpha • Mar 26

Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients

Summary Foghorn Therapeutics remains a "hold" due to ongoing development of FHD-909 for SMARCA4 solid tumors, with key data expected by late 2025/early 2026. Partnership with Eli Lilly strengthens FHD-909's prospects, focusing on NSCLC patients with SMARCA4 mutation & other programs; Upfront $380 million payment and up to $1.3 billion milestone payments. Preclinical results of FHD-909 combined with KEYTRUDA and KRAS inhibitors will be presented at AACR in April 2025, offering an early catalyst. The global non-small lung carcinoma market is predicted to reach $21.51 billion by the end of 2033; Up to 10% of NSCLC solid tumors express SMARCA4 mutation. Read the full article on Seeking Alpha
분석 기사 • Feb 23

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 29% But Growth Is Lacking

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders are no doubt pleased to see that the share price has bounced 29...
분석 기사 • Feb 08

Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Jan 01

More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41%

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders that were waiting for something to happen have been dealt a blow...
분석 기사 • Nov 07

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) just released its third-quarter report and things are looking bullish...
분석 기사 • Oct 22

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

The Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) share price has softened a substantial 28% over the previous 30 days...
분석 기사 • Sep 01

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

The Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) share price has done very well over the last month, posting an excellent...
분석 기사 • Jul 17

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shares have had a really impressive month, gaining 27% after a shaky period...
분석 기사 • May 09

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders are probably feeling a little disappointed, since its shares...
분석 기사 • Apr 12

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Feb 22

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders would be excited to see that the share price has had a great...
분석 기사 • Dec 13

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Those holding Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shares would be relieved that the share price has rebounded 33...
분석 기사 • Nov 07

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Shareholders in Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) may be thrilled to learn that the analysts have just...
분석 기사 • Jun 14

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 10

Foghorn Therapeutics: Selling For Less Than Cash Value

Summary Today, we put Foghorn Therapeutics in the spotlight for the first time. The company is developing several early stage drug candidates, and the stock trades currently for less than the net cash on the balance sheet. An investment analysis follows in the paragraphs below. One of the advantages of being disorganized is that one is always having surprising discoveries.”― A.A. Milne Today, we take our first look at Foghorn Therapeutics Inc. (FHTX). This small biotech concern came public in 2020 and now finds itself in Busted IPO territory. In a testament to how cruel 2022 has been to small biotech concerns, Foghorn is one of myriad biotech stocks that currently trade for less than the net cash on its balance sheet. The company does have a bevy of early stage drug candidates currently in development. An analysis follows below. Seeking Alpha Company Overview: Foghorn Therapeutics is based just outside of Boston in Cambridge, MA. This clinical-stage biopharmaceutical company is focused on developing medicines targeting genetically determined dependencies within the chromatin regulatory system. The company develops drug candidates utilizing its proprietary Gene Traffic Control platform that identifies and validates potential drug targets within the system. The stock currently trades for just over $8.00 a share and sports an approximate market capitalization of $330 million. September Company Presentation The company is utilizing enzyme inhibition and protein degradation approaches to potentially treat cancers, including uveal melanoma and synovial sarcoma. Foghorn is targeting one of the ways cells regulate gene expression by using chromatin in the so-called chromatin gene regulatory system. It has dubbed this approach "Gene Traffic Control." Foghorn has developmental partnership deals with drug giants Merck (MRK) and Eli Lilly (LLY). The partnership with Loxo Oncology, a division of Lilly, brought in a $380 million upfront payment. The one with Merck consisted of a $15 million upfront payment as well as a potential $410 million in various milestone payouts. September Company Presentation As you can see above, most of the candidates within Foghorn's pipeline are early staged and partnered with larger drug players. One of its wholly owned candidates is FHD-286. This compound is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM and is targeting multiple indications. September Company Presentation FHD-286 is in Phase I development. Unfortunately, in late August the FDA slapped a full clinical hold on the Foghorn's phase 1 dose escalation study of FHD-286 in patients with relapsed and/or refractory acute myelogenous leukemia ((AML)) and myelodysplastic syndrome [MDS]. This follows a partial hold issued in May and comes as a result of additional suspected cases of fatal differentiation syndrome. The FDA has questions, and this will require further analysis before the hold could be potentially lifted. A Phase 1 dose escalation study of FHD-286 in metastatic uveal melanoma (mUM) will continue as plan. Initial results from this trial should be out in the first half of 2023. September Company Presentation The company is currently enrolling patients in a Phase 1 clinical study evaluating FHD-609 in synovial sarcoma is also due out in 2023. FHD-609 is a potent and selective heterobifunctional protein degrader of BRD9. September Company Presentation All the partnered candidates in Foghorn's pipeline are in even earlier stages of development. The company did receive $4.5 million worth of collaboration revenue via its partnership with Loxo Oncology in the second quarter and will receive a $5 million milestone payout from Merck in the third quarter. Analyst Commentary & Balance Sheet: So far in 2022, Wedbush, Goldman Sachs ($21 price target) and H.C. Wainwright ($25 price target) have reissued Buy ratings on Foghorn Therapeutics, while Morgan Stanley ($15 price target) has maintained a Hold rating on the stock.
Seeking Alpha • Aug 23

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

The U.S. Food and Drug Administration (FDA) placed a full clinical hold on Foghorn Therapeutics' (NASDAQ:FHTX) phase 1 dose escalation study of FHD-286 in patients with relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after additional suspected cases of fatal differentiation syndrome. The FDA had placed partial hold on the study in May following the report of a death due to a potential differentiation syndrome. The company said in an Aug. 23 press release that the full clinical hold in the study was due to the observation, in the data submitted in response to the partial hold, of additional suspected cases of fatal differentiation syndrome believed to be linked with FHD-286. Foghorn added that Differentiation syndrome is linked with AML/MDS therapies which induce differentiation, an effect that has been seen with, and is believed to be on-target for, the proposed mechanism of action for FHD-286. The FDA has additional questions and requires further analyses before the clinical hold may be lifted, the company noted. Foghorn said that a dose escalation phase 1 trial of FHD-286 in metastatic uveal melanoma (mUM) continues per protocol and it plans to report data in H1 2023. FHTX -18.38% to $11.99 premarket Aug. 23
Seeking Alpha • Aug 09

Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M

Foghorn Therapeutics press release (NASDAQ:FHTX): Q2 GAAP EPS of -$0.66 misses by $0.07. Revenue of $4.49M (+1503.6% Y/Y).
Seeking Alpha • Jun 02

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Foghorn has partnering deals with major big pharma. They have a novel technology which no one else seems to have. If they can do proof of concept, they may go up considerably.
분석 기사 • Apr 13

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

주주 수익률

FHTXUS BiotechsUS 시장
7D11.3%1.2%1.1%
1Y1.9%34.6%28.7%

수익률 대 산업: FHTX은 지난 1년 동안 34.6%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.

수익률 대 시장: FHTX은 지난 1년 동안 28.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.

주가 변동성

Is FHTX's price volatile compared to industry and market?
FHTX volatility
FHTX Average Weekly Movement9.4%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

안정적인 주가: FHTX는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: FHTX의 주간 변동성(9%)은 지난 1년 동안 안정적이었습니다.

회사 소개

설립직원 수CEO웹사이트
2015106Adrian H. Gottschalkfoghorntx.com

임상 단계의 바이오 제약 회사인 포그혼 테라퓨틱스는 미국의 염색질 조절 시스템 내에서 유전적으로 결정된 의존성을 표적으로 하는 의약품을 발견하고 개발하는 회사입니다. 이 회사는 독점적인 유전자 교통 제어 플랫폼을 사용하여 시스템 내에서 약물 표적을 식별, 검증하고 잠재적으로 약물 표적을 찾아냅니다. 이 회사는 돌연변이, 비소세포폐암, 자궁내막암, 자궁경부암, 난소암, 방광암, 미만성 거대 B세포 림프종, 다양한 급성 골수성 백혈병 및 골수형성이상증후군 치료제를 개발하고 있습니다.

Foghorn Therapeutics Inc. 기초 지표 요약

Foghorn Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
FHTX 기초 통계
시가총액US$247.77m
순이익 (TTM)-US$75.32m
매출 (TTM)US$28.22m
8.8x
주가매출비율(P/S)
-3.3x
주가수익비율(P/E)

FHTX는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
FHTX 손익계산서 (TTM)
매출US$28.22m
매출원가US$82.10m
총이익-US$53.87m
기타 비용US$21.45m
순이익-US$75.32m

최근 보고된 실적

Mar 31, 2026

다음 실적 발표일

해당 없음

주당순이익(EPS)-1.28
총이익률-190.88%
순이익률-266.88%
부채/자본 비율0%

FHTX의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/24 13:26
종가2026/05/22 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Foghorn Therapeutics Inc.는 15명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Yuan ZhiB. Riley Securities, Inc.
Kalpit PatelB. Riley Securities, Inc.
Suranjit MukherjeeBTIG